Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 182
- Registration Number
- NCT00141921
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 170
- Registration Number
- NCT00135304
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Phase 3
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Amgen
- Registration Number
- NCT00135317
Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 564
- Registration Number
- NCT00132418
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
Phase 4
Completed
- Conditions
- Kidney DiseaseSecondary HyperparathyroidismChronic Kidney Disease
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT00132431
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 241
- Registration Number
- NCT00131638
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00127842
FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
Phase 4
Completed
- Conditions
- Neutropenia
- Interventions
- Other: PI Discretion
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2252
- Registration Number
- NCT00125723
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00124111
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
Phase 3
Completed
- Conditions
- Kidney Disease
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2008-06-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00124098
© Copyright 2025. All Rights Reserved by MedPath